Evaluation of Treatments for the Vaccination against Hepatitis B+Thymopentine

Abstract

We have studied a series of 43 patients – who were suffering from uremia, subject to hemodialysis treatment, resulting seronegative to the test for HBV and who had never been vaccinated before – considering the HBS antibody as seroconversion index. We subdivided our patients into three groups, according to the treatment employed. First group: French vaccine; 2nd group: French vaccine + thymopenthine; 3rd group: recombining DNA vaccine + thymopentine. From a statistical point of view, in the 3rd group we obtained a significant seroconversion in terms of patients, if compared with the other groups.

Meta‐analysis: the adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in end‐stage renal disease

“…One report gave complete information on three clinical trials 24 . A total of 272 unique patients were included in our meta‐analysis 24–29 …”